• 1
    Adam, A., Ers, P., Herman, G., Stas, J.L. (1985) Analytical evaluation of a new latex agglutination test for quantitative determination of C-reactive protein by laser nephelometry. Journal of Clinical Chemistry and Clinical Biochemistry, 23, 787 791.
  • 2
    Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Thyss, H., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. New England Journal of Medicine, 335, 91 97.
  • 3
    Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J.F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., Klein, B. (1995) Biological effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685 691.
  • 4
    Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., Epstein, J. (1994) Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84, 3063 3068.
  • 5
    Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanaka, H., Kuramoto, A., Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83 85.
  • 6
    Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, J., Aarden, L., Piechaczyk, M., Bataille, R. (1989) A paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood, 73, 517 526.
  • 7
    Klein, B., Wijdenes, J., Zhang, X.G., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clément, C., Morel-Fournier, B., Lu, Z., Mannoni, P., Sany, J., Bataille, R. (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78, 1198 1204.
  • 8
    Mehta, J., Tricot, G., Jagannath, S., Ayers, D., Singhal, S., Siegel, D., Desikan, K., Munshi, N., Fassas, A., Mattox, S., Vesole, D., Crowley, J., Barlogie, B. (1998) Salvage autologous or allogeneic transplantation for multiple myeloma. Bone Marrow Transplantation, 21, 887 892.
  • 9
    Moreau, P., Milpied, N., Mahé, B., Juge-Morineau, N., Rapp, M.J., Bataille, R., Harousseau, J.L. (1999) 220 mg/m2 melphalan followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplantation, 23, 1003 1006.
  • 10
    Samuels, B.J. & Bitran, J.D. (1995) High-dose intravenous melphalan: a review. Journal of Clinical Oncology, 13, 1786 1799.
  • 11
    Vesole, D.H., Barlogie, B., Jagannath, S., Cheson, B., Tricot, G., Alexanian, R., Crowley, J. (1994) High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood, 84, 950 956.
  • 12
    Van Zaanen, H.C.T., Koopmans, R.P., Aarden, L.A., Rensink, H.J.A.M., Stouthard, J.M.L., Warnaar, S.O., Lokhorst, H.M., Van Oers, M.H.J. (1996) Endogenous interleukin-6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL-6 antibodies indicates the existence of a positive feed-back loop. Journal of Clinical Investigations, 98, 1441 1448.